B

Becton Dickinson

Global medical devices, lab equipment supplier

Regulatory Affairs Strategist - Digitalization, Advertising & Promotion

Full-TimeUpdated
$135.5k - $216.8k/yr+ Annual bonus + Potential discretionary LTI bonus
Senior
Bachelor's, Master's
Franklin Lakes, NJ, USA
In PersonOn-site; generally at least 4 days in-office per week. Domestic and international travel approximately 10–20%.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a science, engineering, technology, health-related, or related discipline is required.
  • A minimum of 5 years of progressive experience in Regulatory Affairs, Quality, digital/technology, business systems, or a related function is required.
  • A minimum of 3 years of experience supporting, implementing, or managing business systems within a regulated environment is required.
  • Demonstrated experience partnering with IT or technology organizations to implement and maintain systems following GxP, Computer Systems Validation, and Software Development Lifecycle standards is required.
  • Experience with business requirements, system enhancements, application testing, release management, and validated system lifecycle activities is required.
  • Experience working in the medical device, pharmaceutical, life sciences, or another regulated industry is required.
  • Demonstrated understanding of business application ownership, system lifecycle management, requirements, enhancements, releases, testing, validation, and sustaining operations is required.
  • Working knowledge of regulated business environments, GxP principles, Computer Systems Validation, data integrity, and applicable quality-system requirements is required.
  • Ability to translate complex business and regulatory needs into clear requirements, workflows, and scalable digital solutions is required.
  • Ability to use data, experience, technical knowledge, and sound judgment to identify root causes, evaluate alternatives, manage risk, and implement effective solutions is required.
  • Ability to independently manage multiple initiatives and priorities, establish measurable objectives, and coordinate resources to deliver agreed outcomes is required.
  • Ability to communicate complex technical and business topics clearly to technical teams, end users, Regulatory stakeholders, and leadership is required.
  • Ability to build effective partnerships across Central Regulatory Affairs, Business Units, Regions, TGS, Quality, process owners, vendors, and other stakeholders is required.
  • Ability to influence decisions and priorities across a global matrix without relying solely on direct authority is required.
  • Ability to support organizational and technology change through stakeholder engagement, communications, training, and user-readiness activities is required.
  • Ability to identify opportunities to simplify processes, improve system effectiveness, responsibly leverage AI and automation, enhance data quality, and improve user experience is required.
  • Ability to assess risk, competing priorities, and incomplete information to develop practical solutions and appropriate escalation paths is required.
  • Ability to travel domestically and internationally approximately 10–20% is required.
Responsibilities
  • Serve as the Regulatory Affairs business owner for digital platforms supporting Advertising & Promotion, providing business leadership for platform operations, lifecycle management, enhancements, releases, and continuous improvement.
  • Translate global Advertising & Promotion policies, procedures, process requirements, and regulatory needs established through the global process governance model into scalable system requirements, workflows, and digital capabilities in partnership with the Global Ad/Promo Process Owner.
  • Manage the business platform roadmap by identifying, evaluating, prioritizing, and advancing platform capabilities and improvements related to workflow, AI-enabled capabilities, automation, reporting, integration, data quality, and user experience, in alignment with the broader Regulatory Affairs digital roadmap.
  • Evaluate vendor releases, enhancements, and proposed system changes for business applicability and impact, and partner with TGS, technology partners, and stakeholders to plan and implement changes while maintaining business and validation controls.
  • Lead identification, documentation, and alignment of business and user requirements across Central, Business Unit, and Regional stakeholders to ensure solutions support intended business processes and regulatory needs.
  • Provide Regulatory Affairs business governance and oversight for application configuration, business-controlled data, user access, and role design in partnership with technology and operational teams.
  • Identify data quality and integrity risks, lead or coordinate resolution and escalation, and identify recurring application issues and opportunities for systemic improvement.
  • Lead Power User forums, Change Control Board activities, and other application governance mechanisms to facilitate communication, prioritization, and decision-making.
  • Establish and monitor application metrics to evaluate platform performance, effectiveness, data quality, adoption, and opportunities for continuous improvement.
  • Develop business impact assessments, resource considerations, and cost and timing estimates for proposed enhancements and digital initiatives, as appropriate.
  • Author, review, and approve business-owned application documentation, including standard operating procedures, work instructions, and other controlled documentation, partnering with process owners and Quality and Regulatory stakeholders to ensure alignment with approved processes and requirements.
  • Establish and maintain the application training strategy and associated training materials.
  • Coordinate the development and maintenance of learning content, including eLearning modules, work instructions, and other user-support resources.
  • Drive user readiness, adoption, and effective platform use across Business Units and Regions.
  • Lead Regulatory Affairs business activities associated with the Software Development Lifecycle and Computer Systems Validation for Advertising & Promotion digital platforms.
  • Lead business test planning and execution, including Performance Qualification, User Acceptance Testing, and applicable regression testing.
  • Serve as business test lead and coordinate the development, review, execution, and approval of business test scripts and associated evidence.
  • Review and provide business input and approval for applicable Software Development Lifecycle and validation deliverables.
  • Participate in requirements, design, risk, validation, and release-readiness activities, ensuring alignment among user requirements, business processes, system design, and intended use.
  • Provide business and Regulatory Affairs input into Computer Systems Validation and validation strategies for platform enhancements, releases, and infrastructure changes.
  • Ensure appropriate business readiness before implementation of system changes and enhancements.
Desired Qualifications
  • A master's degree in a business, management, science, engineering, or technology-related field is preferred.
  • Experience supporting Regulatory Affairs digital platforms is preferred.
  • Experience with Advertising & Promotion regulatory processes and/or promotional-material management platforms is preferred.
  • Experience with Veeva or similar regulated content/workflow platforms is preferred.
  • Experience operating in a global, matrixed organization is preferred.

About the company

BD (Becton, Dickinson and Company) is a global medical technology company that designs, manufactures, and sells medical devices, laboratory equipment, and related services for hospitals, labs, clinicians, and biopharma partners. It operates in four segments: Medical Essentials (medication delivery and specimen management devices), Connected Care (medication management and advanced patient monitoring systems), BioPharma Systems (drug delivery systems for pharmaceutical partners), and Interventional (surgical, endovascular, urological, and critical care products). In addition to devices, BD offers connected software, analytics, clinical education, customer portals, and service programs to support its products. The company’s goal is to help healthcare providers improve patient outcomes by enabling safer and more efficient delivery of care through integrated devices, data, and services across the health ecosystem.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 fiscal 2026 revenue rose 5.2% to $4.7 billion, and guidance rose.
  • Fairview adopted BD Vmax 160 on September 14, validating pharmacy automation demand.
  • Arthur Hu joins September 30, 2026 to accelerate AI and enterprise modernization.

What critics are saying

  • BD still faces about 7,090 hernia claims, plus Georgia EtO litigation.
  • June 30, 2026 restructuring included $450 million impairments, signaling portfolio damage.
  • Repeated liability and sterilization verdicts could force another breakup or capital raise.

What makes Becton Dickinson unique

  • BD’s February 9, 2026 Waters spin-off leaves a pure-play MedTech platform.
  • Its Pyxis, Incada, and Vmax 160 stack links dispensing, connected care, and robotics.
  • Sixty-thousand employees and global hospital reach give BD unmatched distribution scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Tuition Reimbursement

Growth & Insights and Company News

6 month growth

10%

1 year growth

10%

2 year growth

10%
PR Newswire
Oct 28th, 2026
BD launches Liverty TIPS stent graft in US for tailored portal hypertension treatment

BD (Becton, Dickinson and Company) launched its Liverty TIPS Stent Graft in the US on October 28, 2026. The device treats portal hypertension, a liver condition that can cause internal bleeding or fluid buildup in the abdomen. The system is a transjugular intrahepatic portosystemic shunt (TIPS) device. It lets physicians tailor treatment to a patient's anatomy, disease progression, and clinical goals, and BD says it is the longest TIPS stent graft on the market. The launch follows use in Europe. It is backed by six-month interim results from the ARCH study, which enrolled 177 patients and is the first IDE study with clinical data on small TIPS diameters of 6-7mm.

Yahoo Finance
Oct 23rd, 2026
Becton Dickinson's US manufacturing deal meets $3.3B earnings forecast for 2029

Becton Dickinson has announced a major US manufacturing agreement ahead of its fiscal 2026 fourth quarter earnings report on November 5. A larger domestic footprint could support supply resilience and service levels, and help its push into recurring, higher value medtech platforms such as BioPharma Systems and BD COR. Analysts expect earnings to grow while sales fall. Consensus sees revenue declining 1.6% a year over three years, with profit margins rising from 7.3% to 15.6% by about 2029. Earnings are forecast to reach $3.3 billion by around September 2029, up from $1.6 billion today. Forecasts range from $2.4 billion to $4.6 billion. Key risks include product quality, regulatory issues, pressure in China, and slowing demand tied to Alaris remediation.

BD
Oct 6th, 2026
BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan

BD celebrates 65 years of manufacturing, innovation and community partnership in Canaan. Generations of Connecticut employees have helped ensure the reliable supply of the BD(R) Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn., Oct. 6, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn., the birthplace of the world's first fully sterile, single-use disposable plastic syringe and the largest syringe manufacturing operation in the United States. The site opened in 1961 with eight employees in a 25,000-square-foot building producing about 10 million syringes a year. The invention of the BD(R) Syringe helped enable the shift away from reusable glass syringes, reducing the risk of patient-to-patient disease transmission. Today, more than 500 employees work at the 385,000-square-foot facility, producing more than 2 billion syringes each year, supporting care from routine vaccinations to critical procedures. Over six decades, the Canaan team has supported major public health efforts, including smallpox eradication, H1N1 vaccination programs and the COVID-19 response. "The BD(R) Syringe was invented here in Canaan as a breakthrough in patient safety and has become an essential part of care around the world, touching 80 patients every second," said Eric Borin, worldwide president, Medication Delivery Solutions at BD. "For 65 years, generations of employees have continued to improve how we manufacture while delivering the quality and precision clinicians count on. This milestone is a testament to their dedication and the difference their work makes for patients every day." BD has invested more than $34 million in the Canaan site over the past five years to expand production capacity, modernize operations and support future growth. This includes three new syringe manufacturing lines and equipment upgrades that strengthen supply assurance. These investments reflect BD's commitment to U.S. manufacturing and to helping healthcare systems maintain reliable access to high-quality medical technologies. "Connecticut has a proud history of turning innovation into products that improve people's lives, and BD's Canaan facility is a powerful example," said Governor Ned Lamont. "For 65 years, this site has supported good jobs, strengthened our manufacturing economy and produced medical devices used in patient care around the world. BD's continued investment in Canaan demonstrates the strength of Connecticut's workforce and the important role our state plays in manufacturing essential healthcare products." A Connecticut legacy with global reach BD leaders, elected officials, employees and community partners gathered at the Canaan facility to celebrate its 65-year history and contributions to healthcare, manufacturing and the regional economy. That legacy is reflected in the generations of employees who have built careers at the site. More than 50 have at least 25 years of service, including 10 who have been with BD for 40 years or more. "BD has been an important part of northwestern Connecticut for 65 years, providing local jobs while manufacturing a product that supports patient care around the world," said State Representative Maria Horn and State Senator Stephen Harding in a joint statement. "The Canaan facility shows how advanced manufacturing can create meaningful opportunities in our communities while making a difference far beyond our state. We congratulate the employees who have made this milestone possible and welcome BD's continued investment in the region." As part of the celebration, BD will announce a $10,000 grant to the Community Health & Wellness Center, a Federally Qualified Health Center that provides accessible, high-quality healthcare to residents of northwestern Connecticut. The grant brings BD's support since 2024 to $90,000 helping fund nutrition programs, emergency assistance and transportation for patients in need. The partnership reflects BD's longstanding commitment to strengthening the communities where employees live and work. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with Becton, Dickinson and Company on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company)

Business Insider
Oct 2nd, 2026
RBC Capital remains a Hold on Becton Dickinson (BDX).

RBC Capital remains a Hold on Becton Dickinson (BDX). Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Hold rating on Becton Dickinson on October 1 and set a price target of $190.00. The company's shares closed yesterday at $178.07. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. Becton Dickinson has an analyst consensus of Moderate Buy, with a price target consensus of $193.30. Based on Becton Dickinson's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.98 billion and a net profit of $377 million. In comparison, last year the company earned a revenue of $5.51 billion and had a net profit of $574 million Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year. Most recently, in August 2026, Thomas Polen, the COB, CEO & Pres of BDX sold 4,152.00 shares for a total of $768,120.00. Read More on BDX:

Class Action Lawyer TN
Sep 23rd, 2026
Compensation in a Tennessee Bard PowerPort Lawsuit.

Compensation in a Tennessee Bard PowerPort Lawsuit. Table of contents. Introduction to the Bard PowerPort Lawsuit. Compensation in a Tennessee Bard PowerPort Lawsuit: Types of compensation that may be available to plaintiffs who are meet the criteria for a PowerPort Lawsuit include both economical and non economical damages. * Tennessee Bard PowerPort Lawsuit: Asserts allegations that Bard's implantable port systems were defectively designed and manufactured, leading to serious injuries in patients who relied on them for long-term vascular access. * Link to Fractures and Blood Clots: These devices, widely used for chemotherapy, long-term IV treatments, and other infusion therapies, have been linked to catheter fractures, infections, blood clots, migration, and vessel damage. * Litigation Landscape: Thousands of injured patients across the country have filed lawsuits claiming that Bard Access Systems, Inc. and its parent company, Becton, Dickinson and Company, failed to properly warn healthcare providers and patients about these risks. * Exposure to Life-Threatening Compications: Plaintiffs allege that flaws in the catheter's material and construction allowed the device to degrade inside the body, exposing them to life-threatening complications and emergency surgeries. * Multidistrict Litigation: All federal Bard PowerPort catheter lawsuits have been consolidated in Multidistrict Litigation (MDL No. 3081) before the United States District Court for the District of Arizona. * Coordinated Pretrial Proceedings: This consolidation allows a single district court to coordinate pretrial proceedings, manage discovery, and set the stage for bellwether trials. * Compensation in Bard PowerPort Lawsuit: Through this litigation, plaintiffs are pursuing financial compensation for their medical expenses, pain and suffering, lost wages, and other damages resulting from defective Bard PowerPort catheter devices. If you or a loved one, sufferd injuries or worse as a result of a defective Bard PowerPort Device, call Tennessee Bard PowerPort Lawsuit Lawyer Timothy L. Miles today. You may be eligible for a PowerPort Lawsuit and potentially be entited to substantial compensation in Bard PowerPort Lawsuit. (855) 846-6529 or [email protected]. The Defective Bard Powerport Device. The Bard PowerPort is an implantable port catheter system used to deliver chemotherapy, fluids, and medications directly into a patient's bloodstream. Lawsuits allege that the catheter's polyurethane material is prone to degrading, cracking, and fracturing. * Catheter Fracture and Fragmentation: Shards of the catheter can chip off and travel through the vascular system. These plastic fragments can puncture blood vessels, the lungs, or the heart. * Life-Threatening Risks: The Defective Bard Powerport Device can cause cardiac punctures, cardiac arrhythmia, pulmonary embolisms (blood clots in the lungs), and severe internal bleeding. * Emergency Surgeries: If a Defective Bard Powerport Device causes port fractures or migrates, patients frequently requireemergency surgical extraction to remove the shards from their blood vessels or organs before fatal damage occurs. Bard PowerPort Lawsuit updates. Bard PowerPort litigation updates (sept. 2026). * Court: U.S. District Court, District of Arizona (Judge David G. Campbell) * Litigatin Process: Currently in the discovery process, including document production, depositions, and testing of explanted devices * Core Allegations: Design defects, failure to warn, and negligent manufacturing * Injuries Reported: Catheter fracture, device migration, blood clots, and severe infections leading to hospitalization or sepsis * Next Phase: Bellwether trials scheduled to evaluate representative cases and guide potential settlements The discovery process has focused heavily on engineering analyses, company testing records, and physician testimony about complications observed in clinical practice. Bellwether cases have been selected to move toward trial, where juries will assess whether Bard's design and warnings were adequate under federal product liability law. While verdicts in bellwether trials apply only to the individual plaintiffs involved, they play an important role in shaping the overall litigation. Jury responses to evidence of design defects and corporate negligence will influence both sides' settlement strategies and may drive the framework for financial compensation across the MDL. Who is eligible for a Bard PowerPort Lawsuit. You may qualify for a PowerPort Lawsuit, if you had a defective Bard PowerPort catheter devices, implanted and developed any of the following complications: * Perforations of tissues, vessels and organs * Infections (sepsis or septic shock) * Deep Vein Thrombosis (DVT) * Hemorrhaging or Bleeding Injuries * Fluid buildup on the heart * Irregular Heartbeat * Severe and persistent pain * Chemotherapy leaking into the body * Wrongful death * Other injuries caused by fractured PowerPort catheter Reports of Defective Bard Powerport Catheter Devices and patient. * Defective Bard Powerport Catheter Devices: Thousands of patients have reported complications involving a catheter failure, migration, and infection after receiving one of the Defective Bard Powerport Catheter Devices, * Polyurethane Catheter: In many cases, the polyurethane catheter - often made with a polymer blend called Chronoflex AL - has fractured or degraded over time. * Seveve Internal Injuries: Fragments of the defective Bard Powerport device,may travel through the blood vessels, leading to vascular damage, embolisms, and other internal injuries. * Emergency Medical Procedures: These failures have triggered emergency medical procedures and even permanent harm for affected users. * Structural Integrithy of Weakened Cathete: Experts argue that the material, which contains high concentrations of barium sulfate to improve imaging visibility, may weaken the structural integrity of the catheter over time. Bard PowerPort MDL continues to grow, with more than 3,000 pending Bard PowerPort Lawsuits filed. * The MDL is overseen by Judge Campbell in the District of Arizona, where the court continues to manage the case through recurring status conference proceedings and structured pretrial scheduling. * New Bard PowerPort Lawsuits are currently being filed by lawyers across the country. * If you were injured or suffered other Bard PowerPort complications, you may be qualify for a PowerPort Lawsuit and potentially be entitled to substantial compensation in Bard PowerPort Lawsuit. If you or a loved one, sufferd injuries or worse as a result of a defective Bard PowerPort Device, call Bard PowerPort Lawsuit Lawyer Timothy L. Miles today. You may be eligible for a PowerPort Lawsuit and potentially be entited to substantial compensation in Bard PowerPort Lawsuit. (855) 846-6529 or [email protected].